Special Issue "Exosomes in Cancers Therapy"
Deadline for manuscript submissions: closed (30 April 2021).
Interests: cancer chemoprevention and treatment; breast, lung and ovarian cancers; Exosomes
Special Issues and Collections in MDPI journals
Interests: 32P-postlabelg techniques; natural compounds and extracts; cancers; exosomes; siRNAs; drugs
Exosomes are biological nanovesicles that are involved in cell-cell communication and have a natural ability to carry functional biomolecules, such as small RNAs, DNAs, and proteins. Because of their size, exosomes are explored as nanodevices for the development of new therapeutic applications. Exosomes are widely distributed in various biological fluids such as blood, urine, and milk. The physical and biological stability, as well as tolerability and the possibility of facile scale-up of manufacturing process makes exosomes an ideal nanoparticle for drug delivery with wide therapeutic applications for various diseases including cancer.
The field of exosome-based therapeutics gained much momentum after successful demonstration of dendritic cell (DC)-derived exosomes for cancer immunotherapy and targeted RNAi delivery. Other cell types that have been used as exosome factories include mesenchymal stem cells (MSCs), human and murine cancer cells, etc. Exosomes from these donor cells were shown to deliver interfering RNAs (siRNA and miRNAs) and therapeutic small molecules (e.g., doxorubicin and curcumin). Immature DCs have favorable properties with respect to immunogenicity and could be modified to express a targeting peptide on their surface. Exosome-like particles and lipids derived from fruits (e.g., grapes and grapefruit) have been examined as an alternative drug carrier. Further, milk-derived exosomes have been demonstrated to serve as a vehicle to deliver both hydrophilic and lipophilic small molecules, including chemotherapeutic drugs and siRNA. However, further knowledge is vital to understand the roles of various types of exosomes and exosome mimitics as delivery vehicle to delivery small and large molecules for cancer therapy.
This Special Issue of Cancers therefore welcomes new research articles and timely reviews on all aspects of exosomes, exosome-mediated delivery, and their role in cancer therapy.
Dr. Farrukh Aqil
Prof. Dr. Ramesh Chandra Gupta
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Drug Delivery
- Extracellular vesicles